Pheochromocytoma Diagnosis, Localization, and Treatment

Langue : Anglais

Auteurs : Pacak Karel, Eisenhofer Graeme, Lenders Jacques

Couverture de l’ouvrage Pheochromocytoma

Résumé
Sommaire
Lectorat
Biographie

Pheochromocytomas are rare but treacherous catecholamine-producing tumors, which if missed or not properly treated, will almost invariably prove fatal. Prompt diagnosis is, therefore, essential for effective treatment, usually by surgical resection. The manifestations are diverse and the tumor can mimic a variety of conditions, often resulting in either erroneous diagnoses or a delayed diagnosis.

Reflecting the recent leaps in understanding this condition, Pheochromocytoma: Diagnosis, Localization, and Treatment provides a comprehensive update on the improvements in the diagnosis, localization, management and treatment of pheochromocytomas ? providing you with the latest cutting edge science alongside best clinical practice. Written by the leading names in the field, the text details the significant developments in understanding the genetics and biology of the tumors, coupled with technological advances in the fields of analytical chemistry, genomics, molecular biology and nuclear medicine.

The most comprehensive book on pheochromocytoma

Provides cutting edge science and clinical guidance
Written by the leading names in the field
Authors present their recently developed novel biochemical test for the diagnosis of Pheochromocytoma

1 Introduction.

2 Historical comments.

3 Pathology.

4 Clinical presentation of pheochromocytoma.

4.1 Signs and Symptoms.

4.2 Differential Diagnosis.

4.3 Special Presentations.

4.3.1 Diagnosis of Pheochromocytoma in Patients with an Incidentally Discovered Adrenal Mass.

4.3.2 Pheochromocytoma as an Endocrine Emergency.

4.3.2.1 Hypertensive Crisis.

4.3.2.2 Hypotension and Shock.

4.3.2.3 Multisystem Failure.

4.3.2.4 Cardiac Emergencies.

4.3.2.5 Acute Peripheral Ischemia.

4.3.2.6 Pulmonary Emergencies.

4.3.2.7 Gastrointestinal Emergencies.

4.3.2.8 Nephrological Emergencies.

4.3.2.9 Neurological Emergencies.

4.3.3 Malignant Pheochromocytoma.

4.3.4 Pheochromocytoma in Children.

4.3.5 Pheochromocytoma in Pregnancy.

4.3.6 Pseudopheochromocytoma.

4.3.7 Factitious Pheochromocytoma.

5 Current trends in genetics of pheochromocytoma.

5.1 MEN Syndromes.

5.1.1 Diagnostic Approaches.

5.2 VHL Syndrome.

5.3 NF Type 1.

5.4 Succinate Dehydrogenase Gene Related Pheochromocytoma.

5.5 Genetic Problems in Sporadic and Other Pheochromocytomas.

6 Catecholamines and adrenergic receptors.

6.1 Synthesis and Sources of Catecholamines.

6.2 Synthesis of Catecholamines in Pheochromocytoma.

6.3 Storage and Release of Catecholamines by the Sympathoadrenal System.

6.4 Uptake and Metabolism of Catecholamines Produced by the Sympathoadrenal System.

6.5 Catecholamine Metabolism in Hepatomesenteric Organs.

6.6 Catecholamines Metabolism and Release by Pheochromocytoma.

6.7 Kinetics and Elimination of Catecholamines and Their Metabolites.

6.8 Pharmacology of Catecholamine Systems: Implications for Pheochromocytoma.

6.9 Physiology of Catecholamine Systems.

6.9.1 Adrenal Medullary Hormone System.

6.9.2 Peripheral Dopamine Systems.

6.10 Adrenergic Receptors and Their Functions.

6.11 Actions of the Catecholamines.

7 Current trends in biochemical diagnosis of pheochromocytoma.

7.1 Biochemical Tests of Catecholamine Excess.

7.2 Measurement Methods.

7.3 Reference Intervals.

7.4 Initial Biochemical Testing.

7.5 Follow-up Biochemical Testing.

7.6 Collection and Storage of Plasma and Urine Specimens.

7.7 Interferences from Diet and Drugs.

7.8 Pharmacologic Tests.

7.9 Additional Interpretative Considerations.

7.10 Summary.

8 Current trends in localization of pheochromocytoma.

8.1 Anatomical Imaging of Pheochromocytoma.

8.1.1 Computed Tomography.

8.1.2 Magnetic Resonance Imaging.

8.2 Functional Imaging of Pheochromocytoma.

8.2.1 MIBG Scintigraphy.

8.2.2 Positron Emission Tomography.

8.2.3 Somatostatin Receptor Scintigraphy (Octreoscan).

8.2.4 Current Imaging Algorithm.

9 Treatment of pheochromocytoma.

9.1 Medical Therapy and Preparation for Surgery.

9.2 Postoperative Management.

10 Future trends and perspectives.

10.1 Genomics in Pheochromocytoma Research.

10.2 Proteomics in Pheochromocytoma Research.

10.3 Future Therapeutic Modalities for Pheochromocytoma.

References.

Index

Endocrinologists, including trainees and residentsOncologists, including trainees and residents

Professor Karel Pacak put together the Pheochromocytoma Research Program at the NIH, one of the most prestigious and largest programs world-wide; published over 80 articles/book chapters on this topic. Introduced new biochemical and imaging approaches to this tumor, especially the use of 18F-fluorodopamine in localization of pheochromocytoma. He also developed new biochemical and imaging algorithms for pheochromocytoma for practicing physicians. Moreover, developed new animal model of metastatic pheochromocytoma. Currently working as the Chief of Section on Medical Neuroendocrinology, NICHD. He is also Professor of Medicine at Georgetown University, Washington DC and Charles University, Prague, Czech Republic.

Dr. Eisenhofer is a clinical biochemist with broad experience in basic and patient-oriented research on neuroedocrine and autonomic nervous system function in health and disease. Relevant achievements include codevelopment with Dr. Jacques Lenders of the first HPLC method for measurements of plasma free metanephrines, a test now used for improved biochemical diagnosis of pheochromocytoma. Dr. Eisenhofer was also responsible for initial development of 18F-fluorodopamine as a positron emission tomographic imaging agent for visualizing sympathetic nerves and neuroendocrine tumors. Dr. Eisenhofer co-chairs the Pheochromocytoma RESsearch Support ORganization (PRESSOR - http://www.pressor.org).

Professor Jacques Lenders did his medical study at the University of Nijmegen, the Netherlands. In 1982 he finished his training for internist and in 1988 he defended his thesis on ‘Blood pressure and catecholamines in essential hypertension’. From august 1991 till january 1993 he was ‘visiting associate’ at the ‘Clinical Neuroscience Branch’ of the ‘National Institute of Neurological Disorders and Stroke’ (National Institutes of Health’, Bethesda, USA). In 2005 he was appointed as professor of Vascular Medicine at the University Me